Mario Boccadoro
Elite in Febrile Neutropenia

Mario Boccadoro

Turin, IT 
Elite in Febrile Neutropenia
Turin, IT 
OverviewLocationsClinical Research

Overview

Mario Boccadoro practices in Turin, Italy. Mr. Boccadoro is rated as an Elite expert by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Multiple Myeloma, Agranulocytosis, Febrile Neutropenia, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 257 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Febrile Neutropenia.

Gender
Male

Locations

Turin, Italy
Other Locations
Citta, Italy
Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)
CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Other
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS
Enrollment Status: Completed
Publish Date: July 22, 2024
Intervention Type: Drug
Study Drugs: Melphalan, Lenalidomide, Prednisone
Study Phase: Phase 3
Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients With Hematologic Malignancies
Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: March 13, 2024
Intervention Type: Other
Study Phase: Not Applicable
Phase II Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Phase II Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Enrollment Status: Terminated
Publish Date: December 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

257 Total Publications

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.
Journal: Haematologica
Published: July 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Boccadoro's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 25 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile